Mercaptamine ophthalmic - Leadiant Biosciences
Alternative Names: Cystaran; Cysteamine; Cysteamine HCl; Cysteamine hydrochloride; Cysteamine ophthalmic solution; Dropcys; LB-201 - Leadiant Biosciences; LB-202; LB201Latest Information Update: 29 Jul 2022
At a glance
- Originator Sigma-Tau Pharmaceuticals
- Developer Leadiant Biosciences; Lucane Pharma
- Class Anti-inflammatories; Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
- Mechanism of Action Glutathione synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cystinosis
Most Recent Events
- 29 Jul 2022 Preclinical trials in Cystinosis (New delivery system) in USA (Ophthalmic) (Leadiant Biosciences Pipeline, July 2022)
- 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
- 01 Apr 2016 The Committee for Medicinal Products for Human Use (CHMP) recommends refusal of marketing authorisation for mercaptamine in European Union